Formulations of sapropterin

By dispersing sapropterin in oil to prepare a stable suspension formulation, the problem of sapropterin's easy oxidative degradation in liquid form is solved, providing a stable sapropterin formulation that is easy for children to use and simplifying the administration process.

CN118984698APending Publication Date: 2024-11-19APR APPLIED PHARMA RESEARCH SA
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380018877.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-02
Filing Date
2023-02-02
Publication Date
2024-11-19

Smart Images

  • Figure CN118984698A_ABST
    Figure CN118984698A_ABST
Patent Text Reader

Abstract

The present disclosure relates to a formulation of sapropterin. The formulation comprises a solid suspension of sapropterin dispersed in an oil. The disclosure also encompasses methods of treatment using the formulations.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present disclosure relates to a formulation of sapropterin. The formulation comprises a solid suspension of sapropterin dispersed in oil. The present disclosure also encompasses a method of treatment using the formulation. Background Art

[0002] Phenylketonuria (PKU) and hyperphenylalaninemia (HPA) are conditions that affect how the body breaks down the amino acid phenylalanine. Patients with PKU and HPA are unable to break down phenylalanine, resulting in elevated levels of the amino acid in the blood and brain. This can lead to brain damage. PKU is a considerable problem in the field of pediatric medicine and is diagnosed shortly after birth through a heel prick blood test.

[0003] Phenylketonuria (PKU) and hyperphenylalaninemia (HPA) are disorders caused by mutations in the phenylalanine hydroxylase gene, resulting in a non-functional liver enzyme phenylalanine-4-hydroxylase (PAH) [Erlandsen 2004], which results in an inability to break down phenylalanine and, in turn, in elevated phenylalanine (Phe) concentrations in the blood and brain. Hyperphenylalaninemia (HPA) can also be caused by a deficiency of tetrahydrobiopterin (BH4), a cofactor for PAH (BH4 deficiency). Phe is an essential amino acid that is not synthesized de novo and must be obtained through the diet. PAH converts Phe to tyrosine, an important precursor of catecholamines and melamine. PKU is an inherited autosomal recessive disease caused by mutations in the PAH gene.

[0004] Previously, the mainstay of treatment for PKU involved placing patients on a restricted, low-Phe diet. Recently, sapropterin, a synthetic dihydrochloride preparation of the biologically active 6R-diastereomer of BH4 [Blau 2010], has been suggested for the treatment of PKU and HPA to restore the activity of phenylalanine hydroxylase. In addition to being a cofactor and cosubstrate for PAH, tetrahydrobiopterin is also a cofactor for several enzymes, such as tyrosine hydroxylase, tryptophan hydroxylase, glycerol ether monooxygenase, and nitric oxide synthase. It is involved in the synthesis of monoamine neurotransmitters, including norepinephrine (norepinephrine), dopamine, and 5-hydroxytryptamine (serotonin), as well as free radical nitric oxide, and patients deficient in BH4 may display neurological symptoms caused by impaired production of these neurotransmitters [Blau 2010].

[0005] The structure of sapropterin, Formula I, is shown below.

[0006]

[0007] Sapropterin is currently prescribed as a tablet or powder. (Formulated sapropterin) is available from Biomarin as 100 mg tablets and 100 mg or 500 mg powder sachets for resuspension. In the case of tablets (100 mg equivalent to 77 mg sapropterin), the formulation contains ascorbic acid, polyvinylpyrrolidone, anhydrous calcium hydrogen phosphate, mannitol, riboflavin, and sodium stearyl fumarate; the ascorbic acid protects the active compound from oxidation [Blau 2010]. Kuvan tablets can be swallowed whole or dissolved in water or apple juice [Kuvan 2016]. The latter results in white insoluble particles remaining in the suspension, which is probably due to the fact that the components of the tablet formulation, including polyvinylpyrrolidone, sodium stearyl fumarate, and dibasic calcium phosphate, are not dissolved.

[0008] Children should not be allowed to chew sapropterin tablets. Due to the acidic nature of the dihydrochloride salt, chewing sapropterin tablets may cause irritation of the mouth or throat. If crushed sapropterin tablets are administered in applesauce or milk substitute, the mouth should be rinsed with water or other liquids to prevent oral irritation. [Striepeke 2009] Dosages may be adjusted within the range of 5 mg / kg to 20 mg / kg per day, depending on the response to treatment, which is monitored by measuring blood Phe [Kuvan 2015].

[0009] Both formulations (powder and tablet) were fairly stable when suspended in various foods and water at 20 mg / mL (62 mM). Regardless of the pH of the food, only 3%-7% of sapropterin was degraded after one hour [Jurecki 2009]. The low degradation rate may be due to at least three factors:

[0010] ●High concentration: resuspension at high concentration reduces the oxidation rate

[0011] ● Ascorbic acid in the formulation acts as a temporary sacrificial substrate for oxidation

[0012] ●Food antioxidants: Most foods will contain endogenous antioxidants.

[0013] Although sapropterin exhibits reasonable stability when exposed to food and water for short periods of time, this is not the case for prolonged exposure. At ambient temperature, sapropterin is unstable in the presence of molecular oxygen. Autooxidation proceeds via a free radical chain reaction mechanism, in which the initiation step proceeds via electron transfer from sapropterin to oxygen. The direct reaction between sapropterin and oxygen acts as an initiator, allowing the superoxide thus formed to further react rapidly with sapropterin, thereby establishing a chain reaction process involving the reduction of molecular oxygen via an intermediate tetrahydrobiopterin radical.

[0014] Therefore, long-term storage of sapropterin will lead to degradation via the above-mentioned oxidation process.

[0015] Sapropterin is readily soluble in water and has acidic properties: the pH of a 1 mM aqueous solution is 3.0, and the pH of a 1 M solution is 0.45.

[0016] The reaction between sapropterin and oxygen is stronger in neutral and alkaline solutions. Due to oxidation, the sapropterin solution turns yellow.

[0017] After one hour of exposure at room temperature, a 0.1 mM aqueous solution of sapropterin degraded by about 25%, while a 1 mM solution degraded by only 2%. After three hours, the 0.1 mM solution degraded by more than 60%, while the 1 mM solution degraded by only 10%. pH is also a key determinant of degradation rate: in 0.1 M phosphate buffer (pH 6.8), the half-life of sapropterin is about 16 minutes at room temperature, and it is completely destroyed within 90 minutes. However, solutions in 0.1 N HCl are stable for several weeks at -20°C [Sigma Datasheet]. Moisture is also a driver of oxidation, with optimal stability being obtained under dry conditions [Jurecki 2009]. Interestingly, the nature of the oxidation byproducts depends on the pH, temperature, and composition of the buffer in which sapropterin is dissolved [Davis 1988].

[0018] Stabilizers (such as DTE and ascorbic acid) can reduce oxidation in solution. However, these compounds can only slow down, not stop, the degradation of sapropterin [Fiege 2004].

[0019] Since sapropterin is oxidized in solution, it is impossible to prepare a liquid preparation of sapropterin. This has brought great difficulties to children taking sapropterin. As mentioned above, it is currently necessary to crush the tablets or use small sachets, and then mix them with food or beverages to administer to children. In addition, beverages or foods containing high concentrations of sapropterin may have matters that need further consideration after administration, such as the need to rinse the child's mouth with water or another beverage to remove any potential sapropterin residues, thereby avoiding the stimulation that may be caused by residual sapropterin.

[0020] Therefore, there is a need for a sapropterin formulation that can be administered in liquid form. In addition, there is a need for a liquid formulation that avoids degradation of sapropterin after long-term storage. There is also a need for a liquid formulation that can be administered without further manipulation after administration. Embodiments of the present disclosure seek to address one or more of these problems. Summary of the invention

[0021] The present disclosure relates to a storage-stable liquid sapropterin formulation. In some embodiments, the formulation comprises a solid suspension of sapropterin dispersed in oil. In some embodiments, the formulation may comprise:

[0022] Granular sapropterin in oil, wherein the sapropterin is present in an amount from about 1% w / v to about 50% w / v.

[0023] In some embodiments, sapropterin can exist in the following amounts: about 1% w / v to about 30% w / v, about 1% w / v to about 25% w / v, about 1% w / v to about 20% w / v, about 5% w / v to about 50% w / v, about 5% w / v to about 30% w / v, about 5% w / v to about 25% w / v, about 5% w / v to about 20% w / v, or about 5% w / v to about 15% w / v. The expression of % w / v relates to g / ml. For example, 10% w / v of sapropterin in oil is equivalent to 0.1g of sapropterin in 1ml oil. In some embodiments, sapropterin can exist in the amount of about 7.5% to about 12.5%. In some embodiments, sapropterin can exist in the amount of about 10% w / v.

[0024] In some embodiments, the formulation may include:

[0025] Particulate sapropterin in oil, wherein the sapropterin is present in an amount of about 0.01 g / ml oil to about 0.5 g / ml oil.

[0026] In some embodiments, sapropterin can be present in the amount of about 0.01 g / ml oil to about 0.3 g / ml oil, about 0.01 g / ml oil to about 0.25 g / ml oil, about 0.01 g / ml oil to about 0.2 g / ml oil, about 0.05 g / ml oil to about 0.50 g / ml oil, about 0.05 g / ml oil to about 0.30 g / ml oil, about 0.05 g / ml oil to about 0.25 g / ml oil, about 0.05 g / ml oil to about 0.20 g / ml oil or about 0.05 g / ml oil to about 0.15 g / ml oil. In some embodiments, sapropterin can be present in the amount of about 0.1 g / ml oil.

[0027] In some embodiments, the formulations of the present disclosure may be liquid. In some embodiments, the formulations of the present disclosure may be used for oral administration.

[0028] In some embodiments, the present disclosure provides an oral formulation comprising:

[0029] Particulate sapropterin in a liquid oil, wherein the sapropterin is present in an amount from about 1% w / v to about 50% w / v.

[0030] In some embodiments, the present disclosure provides an oral formulation, which may include:

[0031] Particulate sapropterin in liquid oil, wherein the sapropterin is present in an amount of about 0.01 g / ml oil to about 0.5 g / ml oil.

[0032] In some embodiments, particulate sapropterin may have a Dv90 of about 170 μm to about 400 μm. In some embodiments, particulate sapropterin may have a Dv90 of about 200 μm to about 400 μm. In some embodiments, the Dv90 may be about 250 μm to about 350 μm.

[0033] In some embodiments, particulate sapropterin in a formulation may have a Dv50 of about 70 μm to about 170 μm. In some embodiments, particulate sapropterin in a formulation may have a Dv10 of about 10 μm to about 60 μm.

[0034] In some embodiments, the granular sapropterin may be dispersed in oil. It will be apparent to those skilled in the art that the granular sapropterin may be unevenly dispersed throughout the oil. During storage, the sapropterin may settle to the bottom of the container storing the formulation. It is desirable to keep the dispersion as long as possible. Therefore, in some embodiments, the oil may be selected so that the granular sapropterin is evenly dispersed throughout the oil. A uniform dispersion of sapropterin may be formed when the formulation is stirred. For example, stirring may be caused by shaking the container in which the formulation is housed.

[0035] In some embodiments, the ability to disperse granular sapropterin can be controlled by the viscosity of the oil or the viscosity of the composition. In some embodiments, the oil can have a viscosity of about 10mPa.s to about 500mPa.s, such as about 10mPa.s to about 100mPa.s or about 20mPa.s to about 50mPa.s. Unless otherwise specified, all viscosity measurements herein are obtained according to the procedure described in Example 8 below.

[0036] In some embodiments, the viscosity of the formulation may be attributed solely to the oil. In some embodiments, the viscosity of the formulation may be altered by additional excipients.

[0037] In some embodiments, the formulation may also include a thickener. The thickener may be selected from any known thickener capable of reducing the precipitation rate of granular sapropterin. In some embodiments, the formulation may include a thickener of about 1% w / v to about 10% w / v. In some embodiments, the thickener may be colloidal silicon dioxide. In some embodiments, the formulation may include colloidal silicon dioxide of about 1% w / v to about 10% w / v.

[0038] In some embodiments, the viscosity of the formulation can be about 150 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months. In some embodiments, the viscosity of the formulation can be about 150 mPa.s to about 750 mPa.s after storage at 40°C and 75% relative humidity for 1 month, 3 months, or 6 months.

[0039] When a certain volume is extracted from the preparation, for example, by a syringe or extracted onto a dosing spoon, the uniformity of the preparation can be measured based on the amount of sapropterin in a given volume. The extraction volume of the preparation taken out from the container will have an expected dose, that is, the amount of sapropterin expected to be present in the extraction volume. For example, the preparation may have an expected dose of 0.1g sapropterin in 1mL or 0.5g sapropterin in 5mL. The expected dose can also be given in %w / v form. In some embodiments, the dose provided by the preparation contains sapropterin in an amount that can be 75% to 125% of the expected dose. In some embodiments, the dose provided by the preparation contains sapropterin in an amount that can be 80%-120% or 85%-115% of the expected dose. When provided in a %w / v value, the expected dose can be the same as the amount of sapropterin present in the preparation.

[0040] In some embodiments, the preparation optionally comprises an oil miscible excipient. In some embodiments, the preparation may comprise a mixture of oil and an oil miscible excipient. For example, the oil miscible excipient may be an alcohol (such as ethanol), glycerol, polypropylene glycol or polyethylene glycol. The oil miscible excipient may be a viscosity reducing agent.

[0041] In some embodiments, the oil may comprise fatty acids, fatty acid glycerides, polyols, polyethylene glycol, polypropylene glycol, mineral oil, oils of vegetable origin, monoglycerides, diglycerides, triglycerides, or combinations thereof.

[0042] In some embodiments, the oil may include olive oil, sunflower oil, rapeseed oil, rice bran oil, a combination of capric triglycerides and caprylic triglycerides (e.g. 812) or a combination thereof. In some embodiments, the oil may comprise from about 50% to about 80% caprylic triglyceride (C8) and from about 20% to about 50% capric triglyceride (C10).

[0043] In some embodiments, the formulation may further comprise a flavoring agent. The flavoring agent may be any pharmaceutically acceptable flavoring agent. In some embodiments, the flavoring agent may be selected from the group consisting of orange, lemon, peppermint, strawberry, raspberry, and tutti frutti.

[0044] In some embodiments, the formulation may be free of undesirable excipients. Wherein undesirable excipients are defined as those excipients that are prohibited from being included in oral formulations. In some embodiments, the formulation may be free of excipients that are prohibited from being included in pediatric oral formulations. And for example, in some embodiments, the formulation does not include benzalkonium chloride, benzoic acid and benzoates, benzyl alcohol, ethanol, cetyl trimethyl ammonium bromide (cetrimonium bromide, CTAB), p-benzoate and their salts, or any combination of any of the foregoing substances.

[0045] In some embodiments, the preparation substantially avoids the degradation of sapropterin within a period of 1 month. In some embodiments, the preparation substantially avoids the degradation of sapropterin within a period of 3 months, 6 months, 9 months or 12 months. The avoidance of degradation can be monitored in several ways. The simplest way is to monitor the color change of the preparation. When sapropterin undergoes oxidative degradation, the yellow discoloration in the liquid medium becomes obvious. However, HPLC represents a more robust method for monitoring the degradation of sapropterin. The HPLC program for monitoring the degradation of sapropterin is provided in the embodiments.

[0046] In some embodiments, the formulation may have a shelf life of 1 month. In some embodiments, the formulation may have a shelf life of 3 months. In some embodiments, the formulation may have a shelf life of 6 months. In some embodiments, the formulation may have a shelf life of 9 months. In some embodiments, the formulation may have a shelf life of 12 months, 15 months, 18 months, 21 months, or 24 months.

[0047] In some embodiments, the preparation may be substantially free of degradation products of sapropterin after 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months. In some embodiments, the above-mentioned 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, and 24 months time period refers to storing the preparation of the present disclosure at a controlled temperature and relative humidity for a specified time period. In some embodiments, the temperature may be 25°C or 40°C. In some embodiments, the relative humidity may be 60% or 75%. In some embodiments, the preparation may be stored at 25°C and 60% relative humidity. In some embodiments, the preparation may be stored at 40°C and 75% relative humidity.

[0048] In some embodiments, the degradation product of sapropterin is Compound 1 (also referred to as impurity B), Compound 2 (also referred to as impurity C), or both, as shown below. In some embodiments, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months. In some embodiments, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 40° C. and 75% relative humidity for 1 month, 3 months, or 6 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 40° C. and 75% relative humidity for 1 month, 3 months, or 6 months. In some embodiments, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months. In some embodiments, after storage at 40°C and 75% relative humidity for 1 month, 3 months, or 6 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25°C and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months, Compound 1 and Compound 2 together may be present in a total detectable amount of less than 0.15 w / w% of the amount of sapropterin. In some embodiments, after storage at 40°C and 75% relative humidity for 1 month, 3 months, or 6 months, Compound 1 and Compound 2 together may be present in a total detectable amount of less than 0.15 w / w% of the amount of sapropterin.

[0049]

[0050] In some embodiments, the formulation may contain a detectable amount of Compound 3 (also referred to as impurity H) as shown below. In some embodiments, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3, relative to the peak area of ​​Sapropterin, as measured by HPLC after storage at 25°C and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months. In some embodiments, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3, relative to the peak area of ​​Sapropterin, as measured by HPLC after storage at 40°C and 75% relative humidity for 1 month, 3 months, or 6 months.

[0051]

[0052] In some embodiments, after storage at 25°C and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months or 24 months, the formulation may contain no more than about 0.2% of other impurities in total, except for compounds 1, 2 and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40°C and 75% relative humidity for 1 month, 3 months or 6 months, the formulation may contain no more than about 0.2% of other impurities in total, except for compounds 1, 2 and 3. In some embodiments, after storage at 25°C and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months or 24 months, the formulation may contain any degradation products of sapropterin (including but not limited to compounds 1 and compounds 2) less than 0.1% of the amount of sapropterin. In some embodiments, after storage at 40° C. and 75% relative humidity for 1 month, 3 months, or 6 months, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0053] In some embodiments, after storage at 25°C and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months, the formulation may contain a detectable amount of impurities, but no more than about 1.5% of the total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40°C and 75% relative humidity for 1 month, 3 months, or 6 months, the formulation may contain a detectable amount of impurities, but no more than about 1.5% of the total impurities, as measured by HPLC, relative to the peak area of ​​sapropterin. In some embodiments, after storage at 25°C and 60% relative humidity for 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, or 24 months, the formulation may contain a degradation product of total sapropterin in an amount less than 0.5% of the amount of sapropterin. In some embodiments, the formulation may comprise degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin after storage at 40°C and 75% relative humidity for 1 month, 3 months, or 6 months.

[0054] Also described herein are methods of treating phenylketonuria or hyperphenylalaninemia, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a formulation of the present disclosure.

[0055] In some embodiments, the formulations of the present disclosure may be used in methods of treating phenylketonuria or hyperphenylalaninemia.

[0056] In some embodiments, phenylketonuria and hyperphenylalaninemia can be pediatric phenylketonuria or pediatric hyperphenylalaninemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Embodiments of the present disclosure are further described below with reference to the accompanying drawings, in which:

[0058] Figure 1 is the analysis of an aged sapropterin solution (1 mM) showing a large peak for sapropterin and an emerging peak for oxidation products appearing after 2 hours. DETAILED DESCRIPTION

[0059] The present disclosure relates to a storage-stable sapropterin formulation. In some embodiments, the formulation comprises a solid suspension of sapropterin dispersed in oil. In some embodiments, the formulation may have a shelf life of 1 month. In some embodiments, the formulation may have a shelf life of 3 months. In some embodiments, the formulation may have a shelf life of 6 months. In some embodiments, the formulation may have a shelf life of 9 months. In some embodiments, the formulation may have a shelf life of 12 months. In some embodiments, the formulation may have a shelf life of 15 months. In some embodiments, the formulation may have a shelf life of 18 months. In some embodiments, the formulation may have a shelf life of 21 months. In some embodiments, the formulation may have a shelf life of 24 months.

[0060] As used herein, unless otherwise indicated, the term "about" means ±5% of the stated value, unless the upper limit of the range would exceed 100% of the composition, in which case the upper limit of the range is limited to only 99.9%.

[0061] As used herein, the term "impurity" refers to chemicals that are not sapropterin but may be formed by the synthesis, preparation, processing, degradation or decomposition of sapropterin, including but not limited to degradation products of sapropterin, by-products and intermediates from chemical reactions, and contaminants. As used herein, the term "degradation product" refers to those compounds produced by the degradation of sapropterin. In some embodiments, the formulation may include:

[0062] Granular sapropterin in oil, wherein the sapropterin is present in an amount from about 1% w / v to about 50% w / v.

[0063] In some embodiments, sapropterin can exist in the following amounts: about 1% w / v to about 30% w / v, about 1% w / v to about 25% w / v, about 1% w / v to about 20% w / v, about 5% w / v to about 50% w / v, about 5% w / v to about 30% w / v, about 5% w / v to about 25% w / v, about 5% w / v to about 20% w / v, or about 5% w / v to about 15% w / v. The expression of % w / v relates to g / ml. For example, 10% w / v of sapropterin in oil is equivalent to 0.1g of sapropterin in 1ml oil. In some embodiments, sapropterin can exist in the amount of about 7.5% to about 12.5%. In some embodiments, sapropterin can exist in the amount of about 10% w / v.

[0064] In some embodiments, the formulation may include:

[0065] Particulate sapropterin in oil, wherein the sapropterin is present in an amount of about 0.01 g / ml oil to about 0.5 g / ml oil.

[0066] In some embodiments, sapropterin can be present in the amount of about 0.01 g / ml oil to about 0.3 g / ml oil, about 0.01 g / ml oil to about 0.25 g / ml oil, about 0.01 g / ml oil to about 0.2 g / ml oil, about 0.05 g / ml oil to about 0.50 g / ml oil, about 0.05 g / ml oil to about 0.30 g / ml oil, about 0.05 g / ml oil to about 0.25 g / ml oil, about 0.05 g / ml oil to about 0.20 g / ml oil or about 0.05 g / ml oil to about 0.15 g / ml oil. In some embodiments, sapropterin can be present in the amount of about 0.1 g / ml oil.

[0067] In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 170 μm to about 400 μm, about 170 μm to about 350 μm, about 170 μm to about 300 μm, about 170 μm to about 250 μm, or about 170 μm to about 200 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 180 μm to about 400 μm, about 180 μm to about 350 μm, about 180 μm to about 300 μm, about 180 μm to about 250 μm, or about 180 μm to about 200 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 190 μm to about 400 μm, about 190 μm to about 350 μm, about 190 μm to about 300 μm, about 190 μm to about 250 μm, about 190 μm to about 200 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 200 μm to about 400 μm, about 200 μm to about 350 μm, about 200 μm to about 300 μm, about 200 μm to about 280 μm, about 200 μm to about 260 μm, about 200 μm to about 250 μm, about 200 μm to about 240 μm, or about 200 μm to about 220 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 220 μm to about 400 μm, about 220 μm to about 350 μm, about 220 μm to about 300 μm, about 220 μm to about 250 μm, or about 220 μm to about 240 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 240 μm to about 400 μm, about 240 μm to about 350 μm, about 240 μm to about 300 μm, about 240 μm to about 280 μm, about 240 μm to about 260 μm, or about 240 μm to about 250 μm.

[0068] In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 250 μm to about 400 μm, about 250 μm to about 350 μm, about 250 μm to about 300 μm, about 250 μm to about 280 μm, or about 250 μm to about 260 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 260 μm to about 400 μm, about 260 μm to about 350 μm, about 260 μm to about 300 μm, or about 260 μm to about 280 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 280 μm to about 400 μm, about 280 μm to about 350 μm, about 280 μm to about 340 μm, about 280 μm to about 320 μm, or about 280 μm to about 300 μm.

[0069] In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 300 μm to about 400 μm, about 300 μm to about 380 μm, about 300 μm to about 360 μm, about 300 μm to about 350 μm, about 300 μm to about 340 μm, or about 300 μm to about 320 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 320 μm to about 400 μm, about 320 μm to about 380 μm, about 320 μm to about 360 μm, about 320 μm to about 350 μm, or about 320 μm to about 340 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 340 μm to about 400 μm, about 340 μm to about 380 μm, about 340 μm to about 360 μm, or about 340 μm to about 350 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 350 μm to about 400 μm, about 350 μm to about 390 μm, about 350 μm to about 380 μm, about 350 μm to about 370 μm, or about 350 μm to about 360 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv90 of about 360 μm to about 400 μm, about 360 μm to about 390 μm, about 360 μm to about 380 μm, about 360 μm to about 370 μm, about 370 μm to about 400 μm, about 370 μm to about 390 μm, about 370 μm to about 380 μm, about 380 μm to about 400 μm, or about 390 μm to about 400 μm.

[0070] In some embodiments, the particulate sapropterin in the formulation may have a Dv50 of about 70 μm to about 170 μm, about 70 μm to about 150 μm, about 70 μm to about 130 μm, about 70 μm to about 120 μm, about 70 μm to about 100 μm, or about 70 μm to about 80 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv50 of about 80 μm to about 170 μm, about 80 μm to about 150 μm, about 80 μm to about 130 μm, about 80 μm to about 120 μm, about 80 μm to about 100 μm, or about 80 μm to about 90 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv50 of about 100 μm to about 170 μm, about 100 μm to about 160 μm, about 100 μm to about 150 μm, about 100 μm to about 140 μm, about 100 μm to about 130 μm, about 100 μm to about 120 μm, or about 100 μm to about 110 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv50 of about 110 μm to about 170 μm, about 110 μm to about 160 μm, about 110 μm to about 150 μm, about 110 μm to about 140 μm, about 110 μm to about 130 μm, or about 110 μm to about 120 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv50 of about 120 μm to about 170 μm, about 120 μm to about 160 μm, about 120 μm to about 150 μm, about 120 μm to about 140 μm, or about 120 μm to about 130 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv50 of about 130 μm to about 170 μm, about 130 μm to about 160 μm, about 130 μm to about 150 μm, or about 130 μm to about 140 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv50 of about 140 μm to about 170 μm, about 140 μm to about 160 μm, or about 140 μm to about 150 μm. In some embodiments, particulate sapropterin in the formulation may have a Dv50 of about 150 μm to about 170 μm, about 150 μm to about 160 μm, or about 160 μm to about 170 μm.

[0071] In some embodiments, the particulate sapropterin in the formulation may have a Dv10 of about 10 μm to about 60 μm, about 10 μm to about 50 μm, about 10 μm to about 40 μm, about 10 μm to about 30 μm, or about 10 μm to about 20 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv10 of about 20 μm to about 60 μm, about 20 μm to about 50 μm, about 20 μm to about 40 μm, or about 20 μm to about 30 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv10 of about 30 μm to about 60 μm, about 30 μm to about 50 μm, or about 30 μm to about 40 μm. In some embodiments, the particulate sapropterin in the formulation may have a Dv10 of about 40 μm to about 60 μm, about 40 μm to about 50 μm, or about 50 μm to about 60 μm.

[0072] In some embodiments, the sapropterin particles may have a particle size distribution as shown in Table 1 below:

[0073] Table 1

[0074]

[0075] In some embodiments, the formulation may further comprise a thickener. The thickener may be selected from any known thickener capable of reducing the precipitation rate of particulate sapropterin. In some embodiments, the thickener may be colloidal silicon dioxide.

[0076] In some embodiments, the preparation may include a thickener of about 1% w / v to about 10% w / v. In some embodiments, the preparation may include a thickener of about 1% w / v to about 8% w / v, about 1% w / v to about 6% w / v, about 1% w / v to about 5% w / v, about 1% w / v to about 4% w / v, or about 1% w / v to about 2% w / v. In some embodiments, the preparation may include a thickener of about 2% w / v to about 8% w / v, about 2% w / v to about 6% w / v, about 2% w / v to about 5% w / v, about 2% w / v to about 4% w / v, or about 2% w / v to about 3% w / v. In some embodiments, the preparation may include a thickener of about 3% w / v to about 8% w / v, about 3% w / v to about 6% w / v, about 3% w / v to about 5% w / v, or about 2% w / v to about 4% w / v. In some embodiments, the preparation may include about 4% w / v to about 8% w / v, about 4% w / v to about 7% w / v, about 4% w / v to about 6% w / v, or about 4% w / v to about 5% w / v of thickener. In some embodiments, the preparation may include about 5% w / v to about 8% w / v, about 5% w / v to about 7% w / v, or about 5% w / v to about 6% w / v of thickener. In some embodiments, the preparation may include about 6% w / v to about 8% w / v, about 6% w / v to about 7% w / v, or about 7% w / v to about 8% w / v of thickener. In some embodiments, the preparation may include about 5% w / v of thickener.

[0077] In some embodiments, the preparation may include colloidal silicon dioxide from about 1% w / v to about 10% w / v. In some embodiments, the preparation may include colloidal silicon dioxide from about 1% w / v to about 8% w / v, from about 1% w / v to about 6% w / v, from about 1% w / v to about 5% w / v, from about 1% w / v to about 4% w / v, or from about 1% w / v to about 2% w / v. In some embodiments, the preparation may include colloidal silicon dioxide from about 2% w / v to about 8% w / v, from about 2% w / v to about 6% w / v, from about 2% w / v to about 5% w / v, from about 2% w / v to about 4% w / v, or from about 2% w / v to about 3% w / v. In some embodiments, the preparation may include colloidal silicon dioxide from about 3% w / v to about 8% w / v, from about 3% w / v to about 6% w / v, from about 3% w / v to about 5% w / v, or from about 2% w / v to about 4% w / v. In some embodiments, the preparation may include colloidal silicon dioxide from about 4% w / v to about 8% w / v, from about 4% w / v to about 7% w / v, from about 4% w / v to about 6% w / v, or from about 4% w / v to about 5% w / v. In some embodiments, the preparation may include colloidal silicon dioxide from about 5% w / v to about 8% w / v, from about 5% w / v to about 7% w / v, or from about 5% w / v to about 6% w / v. In some embodiments, the preparation may include colloidal silicon dioxide from about 6% w / v to about 8% w / v, from about 6% w / v to about 7% w / v, or from about 7% w / v to about 8% w / v. In some embodiments, the formulation may comprise about 5% w / v colloidal silicon dioxide.

[0078] In some embodiments, granular sapropterin can be dispersed in oil. In some embodiments, granular sapropterin can be uniformly dispersed in the whole oil. Nevertheless, and in other embodiments, for example, when storing, sapropterin may be precipitated to the bottom of the container storing the preparation, so that granular sapropterin is unevenly dispersed in the whole oil. It is desirable to keep the dispersion as long as possible. Therefore, in some embodiments, oil can be selected so that granular sapropterin is uniformly dispersed in the whole oil. A uniform dispersion of sapropterin can be formed when stirring the preparation. For example, stirring can be caused by shaking the container in which the preparation is housed.

[0079] In some embodiments, the ability to disperse particulate sapropterin can be controlled by the viscosity of the oil or the viscosity of the composition. Therefore, in some embodiments, the oil can have a viscosity of about 10mPa.s to about 500mPa.s, such as about 10mPa.s to about 100mPa.s or about 20mPa.s to about 50mPa.s.

[0080] In some embodiments, the viscosity of the formulation may be attributed solely to the oil. In some embodiments, the viscosity of the formulation may be altered by additional excipients.

[0081] In some embodiments, preparation optionally comprises oil miscible excipient.In some embodiments, oil can be the mixture of oil and oil miscible excipient.For example, oil miscible excipient can be alcohol (such as ethanol), glycerine, polypropylene glycol or polyethylene glycol.In some embodiments, oil miscible excipient can be viscosity reducing agent.

[0082] In some embodiments, oil can comprise short-chain monoglyceride, medium-chain monoglyceride, long-chain monoglyceride, short-chain diglyceride, medium-chain diglyceride, long-chain diglyceride, short-chain triglyceride, medium-chain triglyceride, long-chain triglyceride or their combination.Short chain, medium chain and long chain are art-recognized terms, and relate to the carbon chain length of the fatty acid component of monoglyceride, diglyceride and triglyceride.Short chain glyceride can comprise the fatty acid moiety that carbon chain length is 2 to 5.Medium chain glyceride can have the fatty acid moiety that carbon chain length is 6 to 12.Long chain glyceride can have the fatty acid moiety that carbon chain length is 13 to 26.

[0083] In some embodiments, the fatty acid component of the glycerides can be saturated or unsaturated.

[0084] In some embodiments, oil may include one or more fatty acids. In some embodiments, fatty acids may exist alone or as glycerides. In some embodiments, fatty acids may be selected from the group consisting of: caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, tetracosanoic acid, hexacosanoic acid, myristoleic acid, palmitoleic acid, (Z)-6-sapienic acid (sapienic acid), oleic acid, elaidic acid, vaccenic acid, linoleic acid (linoleic acid), trans-linoleic acid (linolaidic acid), linolenic acid (linolenic acid), arachidonic acid, eicosapentaenoic acid, erucic acid, docosahexaenoic acid or a combination thereof.

[0085] In some embodiments, the oil may comprise fatty acid glycerides selected from the group consisting of caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, and combinations thereof.

[0086] In certain embodiments, oil may include medium chain fatty acid triglycerides. In some embodiments, oil may be a combination of medium chain triglycerides. In some embodiments, oil may be a combination of C8 triglycerides and C10 triglycerides. In some embodiments, oil may include about 50% to about 80% caprylic triglyceride (C8) and about 20% to about 50% capric triglyceride (C10).

[0087] 812 is a medium chain triglyceride containing caprylic acid and capric acid. In some embodiments, 812 may contain from about 50% to about 80% caprylic triglyceride (C8) and from about 20% to about 50% capric triglyceride (C10). In some embodiments, the formulation may contain 812.

[0088] In some embodiments, the oil may comprise fatty acids, fatty acid glycerides, polyols, polyethylene glycol, polypropylene glycol, mineral oil, oils of vegetable origin, monoglycerides, diglycerides, triglycerides, or combinations thereof.

[0089] In some embodiments, the oil may include olive oil, sunflower oil, rapeseed oil, rice bran oil, a combination of capric triglycerides and caprylic triglycerides, or a combination thereof.

[0090] Without wishing to be bound by any particular theory, it is believed that the use of a non-polar solvent as a carrier, such as a combination of capric triglyceride and caprylic triglyceride, slows the rate of autoxidation. Changes in solvent polarity are believed to affect the reaction rate, and autoxidation involves an electron transfer step, which is excluded by using a non-polar solvent as a carrier, since such an ionic process would be primarily promoted by a polar solvent.

[0091] In some embodiments, the viscosity of the formulation may be about 150 mPa.s to about 750 mPa.s after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity. In some embodiments, after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0092] In some embodiments, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, about 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0093] In some embodiments, the viscosity of the formulation can be from about 250 mPa.s to about 750 mPa.s, from about 250 mPa.s to about 700 mPa.s, from about 250 mPa.s to about 650 mPa.s, from about 250 mPa.s to about 600 mPa.s, from about 250 mPa.s to about 550 mPa.s, from about 250 mPa.s to about 500 mPa.s, from about 250 mPa.s to about 450 mPa.s, from about 250 mPa.s to about 400 mPa.s, from about 250 mPa.s to about 350 mPa.s, from about 250 mPa.s to about 300 mPa.s after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0094] In some embodiments, after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, about 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, about 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0095] In some embodiments, after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, about 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0096] In some embodiments, after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, about 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0097] In some embodiments, after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, about 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0098] In some embodiments, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, about 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0099] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, about 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0100] In some embodiments, the viscosity of the formulation can be about 600 to about 750 mPa.s, about 600 to about 700 mPa.s, or about 600 to about 650 mPa.s after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0101] In some embodiments, the viscosity of the formulation can be about 650 to about 750 mPa.s, about 650 to about 700 mPa.s, or about 700 to about 750 mPa.s after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0102] In some embodiments, the viscosity of the formulation may be about 200 mPa.s to about 275 mPa.s after storage for 1 month at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0103] In some embodiments, the viscosity of the formulation may be about 150 mPa.s to about 750 mPa.s after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity. In some embodiments, after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0104] In some embodiments, after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s.

[0105] In some embodiments, after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 250 mPa.s to about 750 mPa.s, about 250 mPa.s to about 700 mPa.s, about 250 mPa.s to about 650 mPa.s, about 250 mPa.s to about 600 mPa.s, about 250 mPa.s to about 550 mPa.s, about 250 mPa.s to about 500 mPa.s, about 250 mPa.s to about 450 mPa.s, about 250 mPa.s to about 400 mPa.s, about 250 mPa.s to about 350 mPa.s, or about 250 mPa.s to about 300 mPa.s.

[0106] In some embodiments, after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, about 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0107] In some embodiments, after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0108] In some embodiments, after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0109] In some embodiments, after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0110] In some embodiments, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0111] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0112] In some embodiments, the viscosity of the formulation can be about 600 to about 750 mPa.s, 600 to about 700 mPa.s, or about 600 to about 650 mPa.s after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0113] In some embodiments, the viscosity of the formulation can be about 650 to about 750 mPa.s, 650 to about 700 mPa.s, or about 700 to about 750 mPa.s after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0114] In some embodiments, the viscosity of the formulation may be about 200 mPa.s to about 275 mPa.s after storage for 3 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0115] In some embodiments, the viscosity of the formulation may be about 150 mPa.s to about 750 mPa.s after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity. In some embodiments, after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0116] In some embodiments, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s after storage at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0117] In some embodiments, after storage for 6 months at 25° C. and 60% relative humidity or 40° C. and 75% relative humidity, the viscosity of the formulation can be about 250 mPa.s to about 750 mPa.s, about 250 mPa.s to about 700 mPa.s, about 250 mPa.s to about 650 mPa.s, about 250 mPa.s to about 600 mPa.s, about 250 mPa.s to about 550 mPa.s, about 250 mPa.s to about 500 mPa.s, about 250 mPa.s to about 450 mPa.s, about 250 mPa.s to about 400 mPa.s, about 250 mPa.s to about 350 mPa.s, or about 250 mPa.s to about 300 mPa.s.

[0118] In some embodiments, after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0119] In some embodiments, after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0120] In some embodiments, after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0121] In some embodiments, after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0122] In some embodiments, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0123] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0124] In some embodiments, the viscosity of the formulation can be about 600 to about 750 mPa.s, 600 to about 700 mPa.s, or about 600 to about 650 mPa.s after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0125] In some embodiments, the viscosity of the formulation can be about 650 to about 750 mPa.s, 650 to about 700 mPa.s, or about 700 to about 750 mPa.s after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0126] In some embodiments, the viscosity of the formulation may be about 200 mPa.s to about 275 mPa.s after storage for 6 months at 25°C and 60% relative humidity or 40°C and 75% relative humidity.

[0127] In some embodiments, the viscosity of the formulation may be from about 150 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 9 months. In some embodiments, after storage for 9 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0128] In some embodiments, after storage for 9 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, about 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s.

[0129] In some embodiments, after storage for 9 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 250 mPa.s to about 750 mPa.s, about 250 mPa.s to about 700 mPa.s, about 250 mPa.s to about 650 mPa.s, about 250 mPa.s to about 600 mPa.s, about 250 mPa.s to about 550 mPa.s, about 250 mPa.s to about 500 mPa.s, about 250 mPa.s to about 450 mPa.s, about 250 mPa.s to about 400 mPa.s, about 250 mPa.s to about 350 mPa.s, about 250 mPa.s to about 350 mPa.s, or about 250 mPa.s to about 300 mPa.s.

[0130] In some embodiments, after storage for 9 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, about 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0131] In some embodiments, after storage for 9 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0132] In some embodiments, after storage for 9 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0133] In some embodiments, after storage for 9 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0134] In some embodiments, after storage for 9 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s.

[0135] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage for 9 months at 25°C and 60% relative humidity.

[0136] In some embodiments, the viscosity of the formulation can be about 600 mPa.s to about 750 mPa.s, 600 mPa.s to about 700 mPa.s, or about 600 mPa.s to about 650 mPa.s after storage at 25°C and 60% relative humidity for 9 months.

[0137] In some embodiments, the viscosity of the formulation can be about 650 mPa.s to about 750 mPa.s, 650 mPa.s to about 700 mPa.s, or about 700 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 9 months.

[0138] In some embodiments, the viscosity of the formulation may be from about 200 mPa.s to about 275 mPa.s after storage at 25°C and 60% relative humidity for 9 months.

[0139] In some embodiments, the viscosity of the formulation may be from about 150 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 12 months. In some embodiments, after storage for 12 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0140] In some embodiments, after storage for 12 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s.

[0141] In some embodiments, after storage for 12 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 250 mPa.s to about 750 mPa.s, about 250 mPa.s to about 700 mPa.s, about 250 mPa.s to about 650 mPa.s, about 250 mPa.s to about 600 mPa.s, about 250 mPa.s to about 550 mPa.s, about 250 mPa.s to about 500 mPa.s, about 250 mPa.s to about 450 mPa.s, about 250 mPa.s to about 400 mPa.s, about 250 mPa.s to about 350 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0142] In some embodiments, after storage for 12 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, about 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0143] In some embodiments, after storage for 12 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0144] In some embodiments, after storage for 12 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0145] In some embodiments, after storage for 12 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0146] In some embodiments, after storage for 12 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s.

[0147] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage for 12 months at 25°C and 60% relative humidity.

[0148] In some embodiments, the viscosity of the formulation can be about 600 mPa.s to about 750 mPa.s, 600 mPa.s to about 700 mPa.s, or about 600 mPa.s to about 650 mPa.s after storage at 25°C and 60% relative humidity for 12 months.

[0149] In some embodiments, the viscosity of the formulation can be about 650 mPa.s to about 750 mPa.s, 650 mPa.s to about 700 mPa.s, or about 700 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 12 months.

[0150] In some embodiments, the viscosity of the formulation may be from about 200 mPa.s to about 275 mPa.s after storage at 25°C and 60% relative humidity for 12 months.

[0151] In some embodiments, the viscosity of the formulation can be about 150 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 15 months. In some embodiments, viscosity measurements are performed by a viscometer based on the protocol described in Example 8. In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0152] In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, about 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s.

[0153] In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 250 mPa.s to about 750 mPa.s, about 250 mPa.s to about 700 mPa.s, about 250 mPa.s to about 650 mPa.s, about 250 mPa.s to about 600 mPa.s, about 250 mPa.s to about 550 mPa.s, about 250 mPa.s to about 500 mPa.s, about 250 mPa.s to about 450 mPa.s, about 250 mPa.s to about 400 mPa.s, about 250 mPa.s to about 350 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0154] In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, about 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0155] In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0156] In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0157] In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0158] In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s.

[0159] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage at 25°C and 60% relative humidity for 15 months.

[0160] In some embodiments, the viscosity of the formulation can be about 600 mPa.s to about 750 mPa.s, 600 mPa.s to about 700 mPa.s, or about 600 mPa.s to about 650 mPa.s after storage at 25°C and 60% relative humidity for 15 months.

[0161] In some embodiments, the viscosity of the formulation can be about 650 mPa.s to about 750 mPa.s, 650 mPa.s to about 700 mPa.s, or about 700 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 15 months.

[0162] In some embodiments, the viscosity of the formulation may be from about 200 mPa.s to about 275 mPa.s after storage at 25°C and 60% relative humidity for 15 months.

[0163] In some embodiments, the viscosity of the formulation may be from about 150 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 18 months. In some embodiments, after storage for 18 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0164] In some embodiments, after storage for 18 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, about 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s.

[0165] In some embodiments, after storage for 18 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 250 mPa.s to about 750 mPa.s, about 250 mPa.s to about 700 mPa.s, about 250 mPa.s to about 650 mPa.s, about 250 mPa.s to about 600 mPa.s, about 250 mPa.s to about 550 mPa.s, about 250 mPa.s to about 500 mPa.s, about 250 mPa.s to about 450 mPa.s, about 250 mPa.s to about 400 mPa.s, about 250 mPa.s to about 350 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0166] In some embodiments, after storage for 18 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, about 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0167] In some embodiments, after storage for 18 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0168] In some embodiments, after storage for 18 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0169] In some embodiments, after storage for 18 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0170] In some embodiments, after storage for 18 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s.

[0171] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage for 18 months at 25°C and 60% relative humidity.

[0172] In some embodiments, the viscosity of the formulation can be about 600 mPa.s to about 750 mPa.s, 600 mPa.s to about 700 mPa.s, or about 600 mPa.s to about 650 mPa.s after storage at 25°C and 60% relative humidity for 18 months.

[0173] In some embodiments, the viscosity of the formulation can be about 650 mPa.s to about 750 mPa.s, 650 mPa.s to about 700 mPa.s, or about 700 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 18 months.

[0174] In some embodiments, the viscosity of the formulation may be from about 200 mPa.s to about 275 mPa.s after storage at 25°C and 60% relative humidity for 18 months.

[0175] In some embodiments, the viscosity of the formulation may be from about 750 mPa.s to about 450 mPa.s after storage at 25°C and 60% relative humidity for 21 months. In some embodiments, after storage for 21 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0176] In some embodiments, after storage for 21 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, about 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s.

[0177] In some embodiments, after storage for 21 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 250 mPa.s to about 750 mPa.s, about 250 mPa.s to about 700 mPa.s, about 250 mPa.s to about 650 mPa.s, about 250 mPa.s to about 600 mPa.s, about 250 mPa.s to about 550 mPa.s, about 250 mPa.s to about 500 mPa.s, about 250 mPa.s to about 450 mPa.s, about 250 mPa.s to about 400 mPa.s, about 250 mPa.s to about 350 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0178] In some embodiments, after storage for 21 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, about 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0179] In some embodiments, after storage for 21 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0180] In some embodiments, after storage for 21 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0181] In some embodiments, after storage for 21 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0182] In some embodiments, after storage for 21 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s.

[0183] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage for 21 months at 25°C and 60% relative humidity.

[0184] In some embodiments, the viscosity of the formulation can be about 600 mPa.s to about 750 mPa.s, 600 mPa.s to about 700 mPa.s, or about 600 mPa.s to about 650 mPa.s after storage at 25°C and 60% relative humidity for 21 months.

[0185] In some embodiments, the viscosity of the formulation can be about 650 mPa.s to about 750 mPa.s, 650 mPa.s to about 700 mPa.s, or about 700 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 21 months.

[0186] In some embodiments, the viscosity of the formulation may be from about 200 mPa.s to about 275 mPa.s after storage at 25°C and 60% relative humidity for 21 months.

[0187] In some embodiments, the viscosity of the formulation may be from about 150 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 24 months. In some embodiments, after storage for 24 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 150 mPa.s to about 700 mPa.s, about 150 mPa.s to about 650 mPa.s, about 150 mPa.s to about 600 mPa.s, about 150 mPa.s to about 550 mPa.s, about 150 mPa.s to about 500 mPa.s, about 150 mPa.s to about 450 mPa.s, about 150 mPa.s to about 400 mPa.s, about 150 mPa.s to about 350 mPa.s, about 150 mPa.s to about 300 mPa.s, about 150 mPa.s to about 250 mPa.s, or about 150 mPa.s to about 200 mPa.s.

[0188] In some embodiments, after storage for 24 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 200 mPa.s to about 750 mPa.s, about 200 mPa.s to about 700 mPa.s, about 200 mPa.s to about 650 mPa.s, about 200 mPa.s to about 600 mPa.s, about 200 mPa.s to about 550 mPa.s, about 200 mPa.s to about 500 mPa.s, about 200 mPa.s to about 450 mPa.s, about 200 mPa.s to about 400 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 350 mPa.s, about 200 mPa.s to about 300 mPa.s, or about 200 mPa.s to about 250 mPa.s.

[0189] In some embodiments, after storage for 24 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 250 mPa.s to about 750 mPa.s, about 250 mPa.s to about 700 mPa.s, about 250 mPa.s to about 650 mPa.s, about 250 mPa.s to about 600 mPa.s, about 250 mPa.s to about 550 mPa.s, about 250 mPa.s to about 500 mPa.s, about 250 mPa.s to about 450 mPa.s, about 250 mPa.s to about 400 mPa.s, about 250 mPa.s to about 350 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0190] In some embodiments, after storage for 24 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 300 mPa.s to about 750 mPa.s, 300 mPa.s to about 700 mPa.s, about 300 mPa.s to about 650 mPa.s, about 300 mPa.s to about 600 mPa.s, about 300 mPa.s to about 550 mPa.s, about 300 mPa.s to about 500 mPa.s, about 300 mPa.s to about 450 mPa.s, about 300 mPa.s to about 400 mPa.s, or about 300 mPa.s to about 350 mPa.s.

[0191] In some embodiments, after storage for 24 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 350 mPa.s to about 750 mPa.s, 350 mPa.s to about 700 mPa.s, about 350 mPa.s to about 650 mPa.s, about 350 mPa.s to about 600 mPa.s, about 350 mPa.s to about 550 mPa.s, about 350 mPa.s to about 500 mPa.s, about 350 mPa.s to about 450 mPa.s, or about 350 mPa.s to about 400 mPa.s.

[0192] In some embodiments, after storage for 24 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 400 mPa.s to about 750 mPa.s, 400 mPa.s to about 700 mPa.s, about 400 mPa.s to about 650 mPa.s, about 400 mPa.s to about 600 mPa.s, about 400 mPa.s to about 550 mPa.s, about 400 mPa.s to about 500 mPa.s, or about 400 mPa.s to about 450 mPa.s.

[0193] In some embodiments, after storage for 24 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 450 mPa.s to about 750 mPa.s, 450 mPa.s to about 700 mPa.s, about 450 mPa.s to about 650 mPa.s, about 450 mPa.s to about 600 mPa.s, about 450 mPa.s to about 550 mPa.s, or about 450 mPa.s to about 500 mPa.s.

[0194] In some embodiments, after storage for 24 months at 25° C. and 60% relative humidity, the viscosity of the formulation can be about 500 mPa.s to about 750 mPa.s, 500 mPa.s to about 700 mPa.s, about 500 mPa.s to about 650 mPa.s, about 500 mPa.s to about 600 mPa.s, or about 500 mPa.s to about 550 mPa.s.

[0195] In some embodiments, the viscosity of the formulation can be about 550 mPa.s to about 750 mPa.s, 550 mPa.s to about 700 mPa.s, about 550 mPa.s to about 650 mPa.s, or about 550 mPa.s to about 600 mPa.s after storage for 24 months at 25°C and 60% relative humidity.

[0196] In some embodiments, the viscosity of the formulation can be about 600 mPa.s to about 750 mPa.s, 600 mPa.s to about 700 mPa.s, or about 600 mPa.s to about 650 mPa.s after storage at 25°C and 60% relative humidity for 24 months.

[0197] In some embodiments, the viscosity of the formulation can be about 650 mPa.s to about 750 mPa.s, 650 mPa.s to about 700 mPa.s, or about 700 mPa.s to about 750 mPa.s after storage at 25°C and 60% relative humidity for 24 months.

[0198] In some embodiments, the viscosity of the formulation may be from about 200 mPa.s to about 275 mPa.s after storage at 25°C and 60% relative humidity for 24 months.

[0199] In some embodiments, the preparation may also include flavorings. The flavoring may be any pharmaceutically acceptable flavoring. In some embodiments, the flavoring may be selected from the group consisting of orange, lemon, peppermint, strawberry, raspberry and candied fruit. In some embodiments, the flavoring may be selected from the group consisting of orange, lemon, peppermint, strawberry, raspberry, candied fruit, holly, sweet mint, spearmint, vanillin, cherry, butterscotch, chocolate, cinnamon, clove, orange, rose, spices, violet, herbs, fruit, grape, pineapple, vanilla, peach, kiwi, papaya, mango, coconut, apple, coffee, plum, watermelon, nuts, green tea, grapefruit, banana, butter, chamomile and combinations thereof.

[0200] In some embodiments, the formulation may include about 0.1% w / v to about 1% w / v of a flavoring agent. In some embodiments, the formulation may include about 0.1% w / v to about 0.8% w / v, about 0.1% w / v to about 0.7% w / v, about 0.1% w / v to about 0.6% w / v, about 0.1% w / v to about 0.5% w / v, about 0.1% w / v to about 0.4% w / v, about 0.1% w / v to about 0.3% w / v, or about 0.1% w / v to about 0.2% w / v of a flavoring agent. In some embodiments, the formulation may include about 0.2% w / v to about 0.8% w / v, about 0.2% w / v to about 0.7% w / v, about 0.2% w / v to about 0.6% w / v, about 0.2% w / v to about 0.5% w / v, about 0.2% w / v to about 0.4% w / v, or about 0.2% w / v to about 0.3% w / v of a flavoring agent. In some embodiments, the formulation may include about 0.3% w / v to about 0.8% w / v, about 0.3% w / v to about 0.7% w / v, about 0.3% w / v to about 0.6% w / v, about 0.3% w / v to about 0.5% w / v, or about 0.3% w / v to about 0.4% w / v of a flavoring agent. In some embodiments, the preparation may include about 0.4% w / v to about 0.8% w / v, about 0.4% w / v to about 0.7% w / v, about 0.4% w / v to about 0.6% w / v, or about 0.4% w / v to about 0.5% w / v of flavoring agent. In some embodiments, the preparation may include about 0.5% w / v to about 0.8% w / v, about 0.5% w / v to about 0.7% w / v, or about 0.5% w / v to about 0.6% w / v of flavoring agent. In some embodiments, the preparation may include about 0.6% w / v to about 0.8% w / v, about 0.6% w / v to about 0.7% w / v, or about 0.7% w / v to about 0.8% w / v of flavoring agent. In some embodiments, the preparation may include about 0.25% w / v of flavoring agent.

[0201] In some embodiments, the formulation may include about 0.1% w / v to about 1% w / v of candied fruit flavoring. In some embodiments, the formulation may include about 0.1% w / v to about 0.8% w / v, about 0.1% w / v to about 0.7% w / v, about 0.1% w / v to about 0.6% w / v, about 0.1% w / v to about 0.5% w / v, about 0.1% w / v to about 0.4% w / v, about 0.1% w / v to about 0.3% w / v, or about 0.1% w / v to about 0.2% w / v of candied fruit flavoring. In some embodiments, the formulation may include about 0.2% w / v to about 0.8% w / v, about 0.2% w / v to about 0.7% w / v, about 0.2% w / v to about 0.6% w / v, about 0.2% w / v to about 0.5% w / v, about 0.2% w / v to about 0.4% w / v, or about 0.2% w / v to about 0.3% w / v of fruit preserves flavoring. In some embodiments, the formulation may include about 0.3% w / v to about 0.8% w / v, about 0.3% w / v to about 0.7% w / v, about 0.3% w / v to about 0.6% w / v, about 0.3% w / v to about 0.5% w / v, or about 0.3% w / v to about 0.4% w / v of fruit preserves flavoring. In some embodiments, the preparation may include about 0.4% w / v to about 0.8% w / v, about 0.4% w / v to about 0.7% w / v, about 0.4% w / v to about 0.6% w / v, or about 0.4% w / v to about 0.5% w / v of preserved fruit flavoring. In some embodiments, the preparation may include about 0.5% w / v to about 0.8% w / v, about 0.5% w / v to about 0.7% w / v, or about 0.5% w / v to about 0.6% w / v of preserved fruit flavoring. In some embodiments, the preparation may include about 0.6% w / v to about 0.8% w / v, about 0.6% w / v to about 0.7% w / v, or about 0.7% w / v to about 0.8% w / v of preserved fruit flavoring. In some embodiments, the preparation may include about 0.25% w / v of preserved fruit flavoring.

[0202] In some embodiments, the preparation may include a sweetener. The sweetener may be any pharmaceutically acceptable sweetener. In some embodiments, the sweetener may be sucrose (sugar), dextrose, maltose, dextrin, xylose, ribose, glucose, lactose, mannose, galactose, fructose (levulose), invert sugar, oligofructose syrup, partially hydrolyzed starch, corn syrup solids, sugar alcohols (such as sorbitol, mannitol, lactitol, maltitol, xylitol and erythritol), artificial sweeteners (such as aspartame), soluble saccharin salts (i.e. saccharin sodium salt or calcium salt), the free acid form of saccharin, acesulfame potassium and combinations thereof.

[0203] In some embodiments, preparations may include a sweetener of about 0.5% w / v to about 15% w / v. In some embodiments, preparations may include a sweetener of about 1% to about 15%, about 1% to about 12.5%, about 1% to about 10%, about 1% to about 7.5%, about 1% to about 5%, or about 1% to about 2.5% w / v. In some embodiments, preparations may include a sweetener of about 2.5% to about 15%, about 2.5% to about 12.5%, about 2.5% to about 10%, about 2.5% to about 7.5%, or about 2.5% to about 5% w / v. In some embodiments, preparations may include a sweetener of about 5% to about 15%, about 5% to about 12.5%, about 5% to about 10%, or about 5% to about 7.5% w / v. In some embodiments, the preparation may include about 7.5% to about 15%, about 7.5% to about 12.5%, about 7.5% to about 10%, about 10% to about 15%, about 10% to about 12.5%, or about 12.5% ​​to about 15% w / v of sweetener. In some embodiments, the preparation may include about 5% w / v of sweetener. In some embodiments, the preparation may include about 10% w / v of sweetener.

[0204] In some embodiments, the formulation may be free of undesirable excipients. Wherein undesirable excipients are defined as those excipients that are prohibited from being included in oral formulations. In some embodiments, the formulation may be free of excipients that are prohibited from being included in pediatric oral formulations. And for example, in some embodiments, the formulation does not include benzalkonium chloride, benzoic acid and benzoates, benzyl alcohol, ethanol, cetyltrimethylammonium bromide (CTAB), p-benzoate and their salts, or any combination of any of the foregoing substances.

[0205] In some embodiments, the formulation may comprise about 10% w / v sapropterin dihydrochloride, about 5% w / v colloidal silicon dioxide, about 0.25% w / v flavoring agent, and an oil, which may comprise about 50% to about 80% caprylic triglyceride (C8) and about 20% to about 50% capric triglyceride (C10). In some embodiments, the formulation may consist essentially of about 10% w / v sapropterin dihydrochloride, about 5% w / v colloidal silicon dioxide, about 0.25% w / v flavoring agent, and an oil, which may comprise about 50% to about 80% caprylic triglyceride (C8) and about 20% to about 50% capric triglyceride (C10). In some embodiments, the formulation may consist of about 10% w / v sapropterin dihydrochloride, about 5% w / v colloidal silicon dioxide, about 0.25% w / v flavoring agent, and oil, which may include about 50% to about 80% caprylic triglyceride (C8) and about 20% to about 50% capric triglyceride (C10). In some embodiments, the oil may consist essentially of about 50% to about 80% caprylic triglyceride (C8) and about 20% to about 50% capric triglyceride (C10). In some embodiments, the oil may consist essentially of about 50% to about 80% caprylic triglyceride (C8) and about 20% to about 50% capric triglyceride (C10).

[0206] 812 is a medium chain triglyceride containing caprylic acid and capric acid. Specifically, 812 contains 50% to 80% caprylic triglyceride (C8) and 20% to 50% capric triglyceride (C10).

[0207] As described above, the formulation avoids degradation of sapropterin in a liquid medium. This is particularly advantageous because previous studies on sapropterin have shown that degradation is rapid and that long-term storage of sapropterin in a liquid medium is not possible.

[0208] The present disclosure may provide a formulation wherein substantially no degradation products of sapropterin are measured by HPLC after storage at 25°C and 60% relative humidity for 1 month. In some embodiments, the formulation may provide substantially no degradation products of sapropterin after storage at 40°C and 75% relative humidity for 1 month.

[0209] In some embodiments, the formulation may contain substantially no degradation products of sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 3 months. In some embodiments, the formulation may provide substantially no degradation products of sapropterin after storage at 40°C and 75% relative humidity for 3 months.

[0210] In some embodiments, the formulation may contain substantially no degradation products of sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 6 months. In some embodiments, the formulation may provide substantially no degradation products of sapropterin after storage at 40°C and 75% relative humidity for 6 months.

[0211] In some embodiments, the formulation can comprise substantially no degradation products of sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 9 months.

[0212] In some embodiments, the formulation can comprise substantially no degradation products of sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 12 months.

[0213] In some embodiments, the formulation can comprise substantially no degradation products of sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 15 months.

[0214] In some embodiments, the formulation can comprise substantially no degradation products of sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 18 months.

[0215] In some embodiments, the formulation can comprise substantially no degradation products of sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 21 months.

[0216] In some embodiments, the formulation can comprise substantially no degradation products of sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 24 months.

[0217] In some embodiments, the formulation may contain an impurity % relative to the peak area of ​​sapropterin as measured by HPLC. In some embodiments, the measurement is performed by HPLC based on the protocol described in Example 8. The impurity % relative to the peak area of ​​sapropterin is defined as follows:

[0218]

[0219] In some embodiments, after storage at 25° C. and 60% relative humidity for 1 month, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1 relative to the peak area of ​​sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 1 month, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1 relative to the peak area of ​​sapropterin.

[0220] In some embodiments, after storage at 25° C. and 60% relative humidity for 3 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 3 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0221] In some embodiments, after storage at 25° C. and 60% relative humidity for 6 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 6 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0222] In some embodiments, after storage at 25° C. and 60% relative humidity for 9 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 9 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0223] In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0224] In some embodiments, after storage for 152 months at 25° C. and 60% relative humidity, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1 relative to the peak area of ​​sapropterin as measured by HPLC. In some embodiments, after storage for 15 months at 25° C. and 60% relative humidity, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1 relative to the peak area of ​​sapropterin as measured by HPLC.

[0225] In some embodiments, after storage at 25° C. and 60% relative humidity for 18 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 18 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0226] In some embodiments, after storage at 25° C. and 60% relative humidity for 21 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 21 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0227] In some embodiments, after storage at 25° C. and 60% relative humidity for 24 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 24 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0228] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 1 month. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 1 month.

[0229] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 3 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 3 months.

[0230] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 6 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 6 months.

[0231] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 9 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 9 months.

[0232] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 12 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 12 months.

[0233] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 15 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 15 months.

[0234] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 18 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 18 months.

[0235] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 21 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 21 months.

[0236] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 24 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 25° C. and 60% relative humidity for 24 months.

[0237] In some embodiments, after storage at 25° C. and 60% relative humidity for 1 month, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 1 month, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0238] In some embodiments, after storage at 25° C. and 60% relative humidity for 3 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 3 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0239] In some embodiments, after storage at 25° C. and 60% relative humidity for 6 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 6 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0240] In some embodiments, after storage at 25° C. and 60% relative humidity for 9 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 9 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0241] In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0242] In some embodiments, after storage at 25° C. and 60% relative humidity for 15 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 15 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0243] In some embodiments, after storage at 25° C. and 60% relative humidity for 18 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0244] In some embodiments, after storage at 25° C. and 60% relative humidity for 21 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 21 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0245] In some embodiments, after storage at 25° C. and 60% relative humidity for 24 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 24 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0246] In some embodiments, after storage at 25° C. and 60% relative humidity for 1 month, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 1 month, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0247] In some embodiments, after storage at 25° C. and 60% relative humidity for 3 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 3 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0248] In some embodiments, after storage at 25° C. and 60% relative humidity for 6 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 6 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0249] In some embodiments, after storage at 25° C. and 60% relative humidity for 9 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 9 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0250] In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0251] In some embodiments, after storage at 25° C. and 60% relative humidity for 15 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 15 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0252] In some embodiments, after storage at 25° C. and 60% relative humidity for 18 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 18 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0253] In some embodiments, after storage at 25° C. and 60% relative humidity for 21 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 21 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0254] In some embodiments, after storage at 25° C. and 60% relative humidity for 24 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 24 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0255] In some embodiments, the formulation may contain no more than about 0.2% of other impurities other than Compounds 1, 2, and 3 in total relative to the peak area of ​​sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity for 1 month. In some embodiments, other impurities may include impurity A (2-amino-5,6,7,8-tetrahydro-pterin-4-ol; reduced pterin), impurity D (2-amino-pterin-4-ol; pterin), impurity E (2,4,5-triamino-6-hydroxy-pyrimidine sulfate; TAP sulfate), impurity F (acetic acid 2-acetoxy-2-(2-amino-4-hydroxy-pterin-6-yl-1-methyl-ethyl ester; diacetylbiopterin) or a combination thereof. In some embodiments, after storage at 25° C. and 60% relative humidity for 1 month, the formulation may contain, in addition to compounds 1, 2 and 3, a total of no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04% or about 0.03% of other impurities relative to the peak area of ​​sapropterin.

[0256] In some embodiments, after storage at 25° C. and 60% relative humidity for 3 months, the formulation may contain no more than about 0.2% of other impurities in total, in addition to compounds 1, 2, and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 3 months, in addition to compounds 1, 2, and 3, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin.

[0257] In some embodiments, after storage at 25° C. and 60% relative humidity for 6 months, the formulation may contain no more than about 0.2% of other impurities in total, in addition to compounds 1, 2, and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 6 months, in addition to compounds 1, 2, and 3, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin.

[0258] In some embodiments, after storage at 25° C. and 60% relative humidity for 9 months, the formulation may contain no more than about 0.2% of other impurities in total, in addition to compounds 1, 2, and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 9 months, in addition to compounds 1, 2, and 3, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin.

[0259] In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, the formulation may contain no more than about 0.2% of other impurities in total, in addition to compounds 1, 2, and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 12 months, in addition to compounds 1, 2, and 3, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin.

[0260] In some embodiments, after storage at 25° C. and 60% relative humidity for 15 months, the formulation may contain no more than about 0.2% of other impurities in total, relative to the peak area of ​​sapropterin, in addition to compounds 1, 2 and 3, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 15 months, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin, in addition to compounds 1, 2 and 3.

[0261] In some embodiments, after storage at 25° C. and 60% relative humidity for 18 months, the formulation may contain no more than about 0.2% of other impurities in total, in addition to compounds 1, 2, and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 18 months, in addition to compounds 1, 2, and 3, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin.

[0262] In some embodiments, after storage at 25° C. and 60% relative humidity for 21 months, the formulation may contain no more than about 0.2% of other impurities, other than compounds 1, 2, and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 21 months, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities, other than compounds 1, 2, and 3, relative to the peak area of ​​sapropterin.

[0263] In some embodiments, after storage at 25° C. and 60% relative humidity for 24 months, the formulation may contain no more than about 0.2% of other impurities in total, in addition to compounds 1, 2, and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 25° C. and 60% relative humidity for 24 months, in addition to compounds 1, 2, and 3, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin.

[0264] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 1 month at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 1 month at 25°C and 60% relative humidity.

[0265] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 3 months at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 3 months at 25°C and 60% relative humidity.

[0266] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 6 months at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 6 months at 25°C and 60% relative humidity.

[0267] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 9 months at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 9 months at 25°C and 60% relative humidity.

[0268] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 12 months at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 12 months at 25°C and 60% relative humidity.

[0269] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 15 months at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 15 months at 25°C and 60% relative humidity.

[0270] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 18 months at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 18 months at 25°C and 60% relative humidity.

[0271] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 21 months at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 21 months at 25°C and 60% relative humidity.

[0272] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 24 months at 25°C and 60% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 24 months at 25°C and 60% relative humidity.

[0273] In some embodiments, after storage at 40° C. and 75% relative humidity for 1 month, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1 relative to the peak area of ​​sapropterin as measured by HPLC. In some embodiments, after storage at 40° C. and 75% relative humidity for 1 month, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1 relative to the peak area of ​​sapropterin.

[0274] In some embodiments, after storage at 40° C. and 75% relative humidity for 3 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40° C. and 75% relative humidity for 3 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0275] In some embodiments, after storage at 40° C. and 75% relative humidity for 6 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.5% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40° C. and 75% relative humidity for 6 months, the formulation may contain a detectable amount of Compound 1, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, or about 0.1% of Compound 1, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0276] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 40° C. and 75% relative humidity for 1 month. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 40° C. and 75% relative humidity for 1 month.

[0277] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 40° C. and 75% relative humidity for 3 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 40° C. and 75% relative humidity for 3 months.

[0278] In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.5% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 40° C. and 75% relative humidity for 6 months. In some embodiments, the formulation may contain a detectable amount of Compound 2, but no more than about 0.45%, about 0.4%, about 0.35%, about 0.3%, about 0.25%, about 0.2%, about 0.15%, about 0.1%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, or about 0.01% of Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC after storage at 40° C. and 75% relative humidity for 6 months.

[0279] In some embodiments, after storage at 40° C. and 75% relative humidity for 1 month, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40° C. and 75% relative humidity for 1 month, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0280] In some embodiments, after storage at 40° C. and 75% relative humidity for 3 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40° C. and 75% relative humidity for 3 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0281] In some embodiments, after storage at 40° C. and 75% relative humidity for 6 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40° C. and 75% relative humidity for 6 months, the formulation may contain detectable amounts of Compound 1 and Compound 2, but no more than about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, or about 0.2% of Compound 1 and Compound 2, relative to the peak area of ​​sapropterin, as measured by HPLC.

[0282] In some embodiments, after storage at 40°C and 75% relative humidity for 1 month, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 40°C and 75% relative humidity for 1 month, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0283] In some embodiments, after storage at 40°C and 75% relative humidity for 3 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​sapropterin as measured by HPLC. In some embodiments, after storage at 40°C and 75% relative humidity for 3 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​sapropterin.

[0284] In some embodiments, after storage at 40°C and 75% relative humidity for 6 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​Sapropterin as measured by HPLC. In some embodiments, after storage at 40°C and 75% relative humidity for 6 months, the formulation may contain a detectable amount of Compound 3, but no more than about 0.15% of Compound 3 relative to the peak area of ​​Sapropterin.

[0285] In some embodiments, the formulation may contain no more than about 0.2% in total of other impurities other than Compounds 1, 2, and 3 relative to the peak area of ​​sapropterin as measured by HPLC after storage at 40°C and 75% relative humidity for 1 month. In some embodiments, other impurities may include impurity A (2-amino-5,6,7,8-tetrahydro-pterin-4-ol; reduced pterin), impurity D (2-amino-pterin-4-ol; pterin), impurity E (2,4,5-triamino-6-hydroxy-pyrimidine sulfate; TAP sulfate), impurity F (acetic acid 2-acetoxy-2-(2-amino-4-hydroxy-pterin-6-yl-1-methyl-ethyl ester; diacetylbiopterin) or a combination thereof. In some embodiments, after storage at 40° C. and 75% relative humidity for 1 month, the formulation may contain, in addition to compounds 1, 2 and 3, a total of no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04% or about 0.03% of other impurities relative to the peak area of ​​sapropterin.

[0286] In some embodiments, after storage at 40°C and 75% relative humidity for 3 months, the formulation may contain no more than about 0.2% of other impurities in total, in addition to compounds 1, 2 and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40°C and 75% relative humidity for 3 months, in addition to compounds 1, 2 and 3, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04% or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin.

[0287] In some embodiments, after storage at 40° C. and 75% relative humidity for 6 months, the formulation may contain no more than about 0.2% of other impurities in total, in addition to compounds 1, 2, and 3, relative to the peak area of ​​sapropterin, as measured by HPLC. In some embodiments, after storage at 40° C. and 75% relative humidity for 6 months, in addition to compounds 1, 2, and 3, the formulation may contain no more than about 0.15%, about 0.1%, about 0.08%, about 0.06%, about 0.05%, about 0.04%, or about 0.03% of other impurities in total, relative to the peak area of ​​sapropterin.

[0288] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 1 month at 40°C and 75% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 1 month at 40°C and 75% relative humidity.

[0289] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 3 months at 40°C and 75% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 3 months at 40°C and 75% relative humidity.

[0290] In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin, as measured by HPLC after storage for 6 months at 40°C and 75% relative humidity. In some embodiments, the formulation may contain detectable amounts of impurities, but no more than about 1.2%, about 1%, about 0.8%, about 0.6%, about 0.5%, or about 0.4% of total impurities, relative to the peak area of ​​sapropterin, after storage for 6 months at 40°C and 75% relative humidity.

[0291] In some embodiments, after 1 month at 25° C. and 60% relative humidity, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin. In some embodiments, after 1 month at 40° C. and 75% relative humidity, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin.

[0292] In some embodiments, after 3 months at 25° C. and 60% relative humidity, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin. In some embodiments, after 3 months at 40° C. and 75% relative humidity, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin.

[0293] In some embodiments, after 6 months at 25° C. and 60% relative humidity, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin. In some embodiments, after 6 months at 40° C. and 75% relative humidity, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin.

[0294] In some embodiments, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin after 9 months at 25°C and 60% relative humidity.

[0295] In some embodiments, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin after 12 months at 25°C and 60% relative humidity.

[0296] In some embodiments, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin after 15 months at 25°C and 60% relative humidity.

[0297] In some embodiments, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin after 18 months at 25°C and 60% relative humidity.

[0298] In some embodiments, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin after 21 months at 25°C and 60% relative humidity.

[0299] In some embodiments, Compound 1 and Compound 2 together may be present in a total amount of less than 0.15 w / w % of the amount of sapropterin after 24 months at 25°C and 60% relative humidity.

[0300] In addition, in some embodiments, after 1 month at 25° C. and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin. In some embodiments, after 1 month at 40° C. and 75% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0301] In some embodiments, after 3 months at 25° C. and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin. In some embodiments, after 3 months at 40° C. and 75% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0302] In some embodiments, after 6 months at 25°C and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin. In some embodiments, after 6 months at 40°C and 75% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0303] In some embodiments, after 9 months at 25° C. and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0304] In some embodiments, after 12 months at 25° C. and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0305] In some embodiments, after 15 months at 25° C. and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0306] In some embodiments, after 18 months at 25° C. and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0307] In some embodiments, after 21 months at 25° C. and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0308] In some embodiments, after 24 months at 25° C. and 60% relative humidity, the formulation may contain any degradation products of sapropterin (including but not limited to Compound 1 and Compound 2) in an amount less than 0.1% of the amount of sapropterin.

[0309] In some embodiments, after 1 month at 25° C. and 60% relative humidity, the formulation may contain degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin. In some embodiments, after 1 month at 40° C. and 75% relative humidity, the formulation may contain degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin.

[0310] In some embodiments, after 3 months at 25° C. and 60% relative humidity, the formulation may contain degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin. In some embodiments, after 3 months at 40° C. and 75% relative humidity, the formulation may contain degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin.

[0311] In some embodiments, after 6 months at 25° C. and 60% relative humidity, the formulation may contain degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin. In some embodiments, after 6 months at 40° C. and 75% relative humidity, the formulation may contain degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin.

[0312] In some embodiments, the formulation may comprise degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin after 9 months at 25°C and 60% relative humidity.

[0313] In some embodiments, after 12 months at 25° C. and 60% relative humidity, the formulation may contain degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin. In some embodiments, after 12 months at 40° C. and 75% relative humidity, the formulation may contain degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin.

[0314] In some embodiments, the formulation may comprise degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin after 15 months at 25°C and 60% relative humidity.

[0315] In some embodiments, the formulation may comprise degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin after 18 months at 25°C and 60% relative humidity.

[0316] In some embodiments, the formulation may comprise degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin after 21 months at 25°C and 60% relative humidity.

[0317] In some embodiments, the formulation may comprise degradation products of total sapropterin in an amount less than 0.5% of the amount of sapropterin after 24 months at 25°C and 60% relative humidity.

[0318] As described above, when a certain volume is extracted from the formulation, for example, by an oral syringe or extracted onto a dosing spoon, the uniformity of the formulation can be measured based on the amount of sapropterin in a given volume. Uniformity can be evaluated according to the content uniformity of the dosage form specified in the European Pharmacopea. For example, content uniformity can be evaluated by measuring 10 units separately using a suitable analytical method. The determination should be carried out on a certain amount of well-mixed material taken out from a single container under normal use conditions. The determination result can be expressed as a delivered dose. The acceptance value can be calculated. The acceptance value can be calculated using the following formula:

[0319]

[0320] Where M is the reference value

[0321] It is the average value of each content, expressed as a percentage of the label requirement

[0322] k is the acceptable level, which is 2.4 or 2.0 depending on the sample size of 10 or 30.

[0323] s is the sample bias.

[0324] In an embodiment of the present disclosure, the formulation provides a dose containing 75% to 125% of the average dose, optionally 80% to 120% or 85% to 115% of the average dose. The average dose can be the average of the above 10 assay samples. Alternatively, the average dose can be the expected dose.

[0325] Without wishing to be bound by a particular theory, it is believed that the preparations disclosed herein may benefit from excluding oxygen from the preparations. A way to achieve this is to optionally use an airtight seal on the container of the preparation. Although an airtight seal may be helpful, any container known in the art for liquid preparations may be suitable for packaging the preparations disclosed herein. For example, and in some embodiments, the container may be a type III amber glass bottle equipped with a TE / CR polypropylene closure with a three-layer seal (expanded polyethylene, EPE). In certain embodiments, the glass bottle may be a 30ml bottle with a 28mm closure. However, any size suitable for this area may be used.

[0326] Example

[0327] These examples are provided for illustrative purposes only, and the embodiments described herein should in no way be construed as being limited to these examples. Rather, the embodiments should be construed to encompass any and all variations that become apparent as a result of the teachings provided herein.

[0328] The following abbreviations are used in these examples: :

[0329]

[0330]

[0331] Example 1

[0332] A 10 liter batch of a formulation of the present disclosure was prepared according to the following procedure.

[0333] Into a suitable 10 litre stainless steel container equipped with a suitable stirrer, add 812N to reach 60% of the required total volume. Colloidal silicon dioxide (5% w / v, 5 g / 100 mL) was added and stirred to dissolve. Orange flavoring (0.5% w / v, 5 g / mL) was then added and stirred to dissolve. Finally, the granular sapropterin was dispersed in the oil and homogenized for 5 minutes.

[0334] Add to 812N up to a final volume of 10 L and continue mixing until homogeneous.

[0335] The homogenous mixture was dispensed into 30 ml portions into appropriately sized amber glass bottles and TE / CR closures were applied.

[0336] Example 2 - Visual Observation

[0337] The stability of unformulated SPT solutions over time was initially investigated by visual inspection of 100 mM solutions. The solutions were observed to be very unstable and developed a yellow / orange color over time, likely due to the formation of oxidation byproducts.

[0338] Sapropterin is a relatively unstable compound and its degradation chemistry is very complex, mainly due to the sensitivity of the side chains and ring moieties to oxidation. The tautomeric equilibrium on the oxidation products further complicates a comprehensive understanding of the precise formation and quantification of all impurities.

[0339] According to the reported literature, the main degradation occurs via oxidation and produces mainly dihydrobiopterin and tetrahydrobiolumazine.

[0340] An overview of the degradation process is given below.

[0341]

[0342] Each of these numbered compounds is also known as:

[0343] 1: Biopterin

[0344] 2: Sepiapterin

[0345] 3:7,8-Dihydrobiopterin

[0346] 4:5,6-dihydrobiopterin

[0347] 5: Pterin

[0348] 6:6R Tetrahydrobiopterin

[0349] 7: 6s tetrahydrobiopterin

[0350] 8. 5,6,7,8,Tetrahydrobiopterin

[0351] Sapropterin samples were subjected to peroxide degradation with 5 mL of 0.1% H2O2 at room temperature for 1.5 hours.

[0352] The HPLC analysis of the obtained oxidative degradation of sapropterin was performed according to the following procedure and the results are shown in Table 2. Impurities B and C (compounds 1 and 2, respectively) were observed to be the major degradation products.

[0353] HPLC parameters:

[0354] Column: YMC Pack ODS AQ (250×4.6)mm, 3μm

[0355] Buffer: Potassium dihydrogen phosphate containing orthophosphoric acid pH 3.0

[0356] Mobile phase A: 100% buffer

[0357] Mobile phase B: acetonitrile:methanol (1:9)

[0358] Wavelength: 220nm for impurities A, C, D, E, G

[0359] Wavelength: 275nm for impurity F

[0360] Flow rate: 0.6ml / min

[0361] Injection volume: 5 μl

[0362] Column temperature: 30°C

[0363] Sample compartment: 5°C

[0364] Run time: 45 minutes

[0365] Preparation of mobile phase:

[0366] Mobile phase A: 2.72 g of potassium dihydrogen phosphate was added to 1000 ml of water and dissolved. The pH was adjusted to 3.0 using orthophosphoric acid. The solution was mixed and filtered through a 0.45 μm nylon membrane filter and degassed.

[0367] Mobile phase B: Dissolve, mix and degas 900 ml of methanol and 100 ml of acetonitrile.

[0368] Preparation of 0.1N HCl: 8.5 ml of hydrochloric acid was added to 900 ml of water, diluted to 1000 ml with water, and then mixed.

[0369] Diluent: 2.72 g potassium dihydrogen phosphate was added to 1000 ml water and dissolved. The pH was adjusted to 3.0 using orthophosphoric acid. 10 mg ascorbic acid was added, mixed, and then filtered through a 0.45 μm nylon membrane filter and degassed.

[0370] Table 2

[0371]

[0372]

[0373] Example 3 HPLC analysis

[0374] Visual observations of degradation of the sapropterin solution were confirmed by HPLC analysis. The following method was used:

[0375] Prior to analysis, samples were diluted to approximately 1 mM.

[0376] HPLC method

[0377] - Column: Partisil 10 μM SCX 250X (from HICHROM)

[0378] -Mode: Isocratic

[0379] -Mobile phase: KH2PO4 30mM, pH 3.0

[0380] - Oven temperature: 30℃

[0381] -Injection volume: 25μL

[0382] - Flow rate: 1.5 mL / min (generating about 60 bar)

[0383] - Detection: DAD 254-360, collected at 254

[0384] HPLC system (VWR Hitachi)

[0385] -VWR Hitachi L-2000 Manager

[0386] -DAD: L2455

[0387] -Automatic sampler: L2200

[0388] -Pump: L2130

[0389] - Column oven: L2350

[0390] Preparation of mobile phase

[0391] 1) V(H2O) = 500 mL

[0392] 2)m(KH2PO4)=2.04g(MW=136.09g / mol)

[0393] 3) Phosphoric acid was diluted 50 times with water (v / v) to reach pH 3

[0394] Note: Before dilution, the phosphoric acid stock solution is 85%

[0395] Note 2: 5g to 8g of a 1 / 50 dilution solution is required to reduce the pH to 3.0

[0396] HPLC analysis was performed on three 100 mM sapropterin aqueous solutions. Each solution was tested at different time points, one when freshly prepared, one after one day, and another after 7 weeks.

[0397] HPLC analysis showed an injection peak at about 2 min and a sapropterin peak at about 7.2 min. Freshly prepared samples did not show any oxidation products. However, samples tested after one day and after 7 weeks showed a peak at 4.2 min, which was attributed to oxidation byproducts appearing between the injection peak and the sapropterin peak.

[0398] Oxidation caused a decrease in the SPT peak over time, but this was not evident over a 24 h period.

[0399] The same analysis was performed on the 1 mM sample. Obviously, the more dilute the sample, the faster the oxidation occurs. The peak of the oxidation byproduct becomes obvious after 2 hours, as shown in Figure 1 shown.

[0400] Example 4: Non-aqueous suspension containing glycerol

[0401] The oxidation of the formulations of glycerol and sapropterin was assessed by observing an increase in orange coloration. The following two formulations were assessed.

[0402] Table 3

[0403]

[0404] As shown in the table above, the glycerol suspension slowed oxidation.

[0405] Example 5: Alternative non-aqueous suspensions

[0406] Oleic acid, olive oil and polypropylene glycol were prepared and oxidation was observed. Formulations were prepared at approximately 10% w / w sapropterin.

[0407] Table 4

[0408]

[0409]

[0410] Example 6: Non-aqueous Suspension Containing Oil-Miscible Components

[0411] Although glycerol has shown promise as a medium for the formulation, it is not desirable due to its viscosity. Therefore, oil-miscible components were examined to reduce the viscosity of the oil. Ethanol was used as an exemplary viscosity reducing agent. The formulation was prepared at about 10% w / w sapropterin.

[0412] Table 5

[0413]

[0414] Oxidation delay was observed in all formulations, and ethanol resulted in a decrease in viscosity.

[0415] Example 7 - Vegetable Oil

[0416] A simple stability study was conducted to determine the stability potential of the formulation being tested. The stability study was conducted at room temperature for one month as this would reflect the conditions under which the material was stored.

[0417] The stability work focused on vegetable oils. Food grade vegetable oils were tested and they were sourced from supermarkets and opened just before the stability work began. Exploratory stability work was then conducted to determine the potential of liquid formulations of sunflower oil, olive oil, rapeseed oil and rice bran oil.

[0418] Stability was informally assessed by preparing a 10% w / w sapropterin suspension and storing it at room temperature on a shelf away from direct sunlight. Separate aliquots were prepared at each time point. At each sampling point, sapropterin was extracted from the oil with water as described below, and the samples were analyzed by HPLC. The absence of degradation products was used to determine the absence of oxidation. The above HPLC method was not validated for quantitative analysis. Instead, the SPT peak size was also used semi-quantitatively to further confirm the absence of oxidation, but this was done by simply overlaying the traces (e.g., SPT peak size at day 0 relative to day 7) rather than performing a calibration curve for SPT.

[0419] A 10% w / w sapropterin suspension was prepared by adding 1 g SPT to 9 g oil and allowed to age at room temperature. Separate aliquots were generated for each time point by following the following extraction and dilution protocol.

[0420] 1. Add 10 g oil + SPT (all stability samples) to a 50 mL falcon tube containing 40 g water (record this mass; mass A) (SPT control, no oil replace this step with the following: add 9 g oil to a 50 mL falcon tube containing 40 g water)

[0421] 2. Mix thoroughly until SPT is completely dissolved.

[0422] 3. Centrifuge: 2000 rpm for 5 min (large centrifuge). The water fraction should be less turbid and should contain 2.5% SPT (79.6 mM)

[0423] 4. Remove most of the oil fraction (be careful not to remove too much of the water fraction)

[0424] 5. Dilute 1 / 100 with water (0.5mL in 50mL). Be careful when doing this to help transfer any remaining oil droplets on the surface. The concentration should be 0.025% (0.796mM)

[0425] - Invert the transfer tube (i.e. draw more than 0.5 mL) so that a drop of oil will remain in the tip when dispensing

[0426] -Wipe the outside of the tip with paper to remove any oil before dispensing 0.5mL

[0427] -Transfer 0.5mL

[0428] - Add 49.5 g of water and record the mass (Mass B)

[0429] Samples were analyzed on day 0, day 5, day 7 and / or day 31.

[0430] Example 7.1 SPT control (no oil)

[0431] For comparison purposes, SPT solutions (in aqueous media) were freshly prepared at the same concentrations used in the stability assay. This provided a comparator for the stability samples in terms of SPT peak size and additional peaks. Note that residual amounts of oxidation products were determined in the freshly prepared solutions. These oxidation products were either already present in the received SPT material or formed during the period between SPT dissolution and HPLC injection (approximately 3 min-5 min).

[0432] Example 7.2 Sunflower oil (SO)

[0433] The extraction procedure effectively avoided 'picking' any potential interferences from the sunflower oil (SO) that could affect the SPT quantification.

[0434] Analysis of stability aliquots showed no signs of oxidation at days 5, 7 and 31 as no increase in oxidation products was observed.

[0435] The absence of degradation products is consistent with visual observations. In particular, the aqueous extracts contained little or no color. However, these aqueous extracts will quickly develop color upon oxidation of SPT, further illustrating the oxidative vulnerability of SPT when in water.

[0436] After 2 months, there was a thin layer of light brown material at the interface of the oil and SPT precipitate. This may be due to residual oxidation of SPT during oil storage.

[0437] Example 7.3 Olive oil

[0438] Stability work showed no signs of oxidation by HPLC analysis at day 7 and day 31.

[0439] After 2 months, unlike the sunflower oil preparation, there was no thin layer of darker material clearly visible at the oil-sediment interface.

[0440] Example 7.4 Rapeseed oil

[0441] Analysis of stability aliquots showed no signs of oxidation by HPLC at day 7 and day 31.

[0442] After 2 months, a layer of lightly colored material formed at the interface of the oil and SPT precipitate.

[0443] Example 7.5 Rice bran oil

[0444] Analysis of stability aliquots showed no signs of oxidation (ie, no visible oxidation products) by HPLC at days 7 and 31.

[0445] To confirm the absence of oxidation, an aliquot of the aqueous extract on day 31 was aged for 20 min and reanalyzed. This resulted in the appearance of a significant oxidation peak, but very little change in the SPT size. These observations suggest that the appearance of the oxidation peak is a more sensitive measure of oxidation (rather than the size of the SPT peak).

[0446] Likewise, as per sunflower oil, a thin layer of darker material was visible after 2 months, but this was not as obvious as with sunflower oil.

[0447] Example 8 Miglyol 812

[0448] Example 8.1

[0449] A 100 mg / ml sapropterin sample was prepared in the same manner as in Example 1. The sample was stored at 25°C / 60% RH in a 30 ml amber Type III glass bottle equipped with a tamper-evident / child-resistant closure. The 100 mg / ml sapropterin formulation is shown below.

[0450] Table 6

[0451]

[0452] Viscosity Measurement Operating Parameters and Procedures

[0453] Instrument: Drawell Analytical NDJ-5S

[0454] Spindle: RV-2

[0455] Spindle speed: 60rpm

[0456] Sample temperature: 25°C

[0457] Sample volume: 25 ml in small volume adapter

[0458] Place a sample of Sapropterin Oral Suspension in a 25°C water bath and allow the sample to reach 25°C. Attach a No. 2 RV spindle and select the correct spindle setting and spindle speed on the viscometer. Pour 25 ml of sample into the small volume adapter. Immerse the spindle in the sample and secure the adapter to the viscometer with the knurled screw. When the reading on the viscometer stabilizes, record the viscosity value.

[0459] HPLC analysis

[0460] Sample preparation: Approximately 0.5 g of sapropterin oral suspension or placebo was dispensed into a 100 ml amber volumetric flask. 80 ml of methanol was added and the sample was then sonicated in ice water for 10 minutes and allowed to equilibrate to room temperature. The sample was then diluted to volume with methanol and shaken to mix. 5 ml of this solution was then placed in a 50 ml amber volumetric flask and made up to volume with methanol. The sample solution was then filtered into an amber HPLC vial using a puradisc 25 NYL filter, removing the first few milliliters.

[0461] HPLC parameters

[0462] Column: Luna 10μm SCX 250×4.6mm

[0463] Column temperature: 30°C

[0464] Buffer: 50 mM potassium dihydrogen phosphate pH 2.5 containing orthophosphoric acid

[0465] Mobile phase: 100% buffer

[0466] Flow rate: 1.5ml / min

[0467] Detection: 220nm UV

[0468] Injection volume: 25 μl

[0469] Run time: 25 minutes

[0470] Sample temperature: 5.0℃±1℃

[0471] The approximate and relative retention times of the impurities are shown in the table below.

[0472] Table 7

[0473] identity Retention time Relative retention time Impurity A 29.37 1.63 Impurity B 9.943 0.55 Impurity C 6.543 0.36 Impurity D 12.318 0.68 Impurity H 22.472 1.25 Unknown at about 14 minutes 14.066 0.78 Sapropterin 18.035 1

[0474] Analysis of the formulations shown in Table 8 at 0, 1 and 3 months is shown in Table 8A.

[0475] Table 8

[0476]

[0477] Table 8A

[0478]

[0479]

[0480] The 6, 9 and 12 month analyses are shown in the table below.

[0481] Table 9

[0482]

[0483]

[0484] HPLC analysis of samples at the 12 month time point is shown in the table below. The major degradation product observed was Impurity B.

[0485] Table 10

[0486]

[0487] The above data supports a shelf life of 12 months.

[0488] Example 8.2

[0489] Another sample prepared in the same manner as Example 8.1 was stored at 40°C / 75% RH in a 30 ml amber Type III glass bottle equipped with a tamper evident / child resistant closure. HPLC analysis was also performed in the same manner as Example 8.1. The 0, 1 and 3 month analyses are shown in the table below.

[0490] Table 11

[0491]

[0492]

[0493] The 6-month analysis is shown in the table below.

[0494] Table 12

[0495]

[0496] The above data supports a shelf life of 12 months.

[0497] Example 9

[0498] For 5 samples Dispersion stability analysis. The first three formulations are the same as Example 8, but have different particle size distributions. The first formulation has a particle size distribution of 15.9 microns Dv10, 81 microns Dv50, and 248 microns Dv90. The second formulation has a particle size distribution of 17.7 microns Dv10, 111 microns Dv50, and 282 microns Dv90. The third formulation has a particle size of 36 microns Dv10, 150 microns Dv50, and 388 microns Dv90. The fourth and fifth formulations include orange flavoring instead of candied fruit flavoring.

[0499] The sample was shaken by hand and 20 ml was transferred to a disposable glass cell for analysis.

[0500] Analysis parameters

[0501] Temperature: 25℃

[0502] Duration: 3 days

[0503] All five samples were sufficiently stable. The first and fourth samples showed slight variations in delta-backscattering signals at the top and bottom of the vial, indicating instability due to particle migration toward the bottom of the vial (i.e., sedimentation). Stability Index ( The stability index (TSI) was less than 0.5 after 3 days, confirming that all samples were stable.

[0504] Example 10

[0505] For 2 other samples Dispersion stability analysis. These two formulations are the same as Example 8, but have different particle size distributions. The first formulation has a particle size distribution of 15.9 microns Dv10, 81 microns Dv50, and 248 microns Dv90. The second formulation has a particle size distribution of 13 microns Dv10, 73 microns Dv50, and 172 microns Dv90.

[0506] The sample was shaken by hand and 20 ml was transferred to a disposable glass cell for analysis.

[0507] Analysis parameters

[0508] Temperature: 25℃

[0509] Duration: 3 days

[0510] Both samples were very stable. The signal changes of delta-backscatter at the bottom and top of the samples were not significant. After 3 days, the TSI of the first sample was about 0.18, and the TSI of the second sample was about 0.23, confirming that both samples were stable.

[0511] Throughout the description and claims of this specification, the words "comprise" and "contain" and their variations mean "including but not limited to", and they are not intended to (and do not) exclude other parts, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context requires otherwise. In particular, where the indefinite article is used, the specification should be understood to contemplate the plural as well as the singular unless the context requires otherwise.

[0512] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the present disclosure are to be understood as being applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All features disclosed in this specification (including any appended claims, specification abstract and drawings) and / or all steps of any method or process so disclosed may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The present disclosure is not limited to the details of any foregoing embodiments. The present disclosure extends to any novel feature or any novel combination of features disclosed in this specification (including any appended claims, specification abstract and drawings), or to any novel step or any novel combination of steps of any method or process so disclosed.

[0513] Although the present invention has been described in conjunction with specific aspects of the present invention, it is apparent that many substitutions, modifications and variations will be apparent to those skilled in the art. Therefore, it is intended to cover all such substitutions, modifications and variations that fall within the spirit and broad scope of the appended claims.

Claims

1. A preparation comprising: Granular sapropterin in oil, wherein the sapropterin is present in an amount of about 1% w / v to about 50% w / v.

2. The formulation of claim 1, wherein the sapropterin is present in an amount of about 1% w / v to about 30% w / v, about 1% w / v to about 25% w / v, about 1% w / v to about 20% w / v, about 5% w / v to about 50% w / v, about 5% w / v to about 30% w / v, about 5% w / v to about 25% w / v, about 5% w / v to about 20% w / v, or about 5% w / v to about 15% w / v.

3. The formulation of claim 1 or claim 2, wherein the particulate sapropterin has a Dv90 of about 170 μm to about 400 μm.

4. A formulation according to any preceding claim, wherein upon agitation of the formulation, the formulation is a homogenous dispersion.

5. A formulation according to any preceding claim, wherein the oil has a viscosity of from about 10 mPa.s to about 500 mPa.s.

6. A formulation according to any preceding claim, wherein the formulation further comprises a thickener.

7. The formulation of claim 6, wherein the thickening agent is colloidal silicon dioxide.

8. A formulation according to any preceding claim further comprising an oil-miscible excipient.

9. The formulation of claim 8, wherein the oil-miscible excipient comprises alcohol, glycerol, polypropylene glycol, polyethylene glycol, or a combination thereof.

10. The formulation of any preceding claim, wherein the oil comprises a fatty acid, a fatty acid glyceride, a polyol, a polyethylene glycol, a polypropylene glycol, a mineral oil, an oil of vegetable origin, a monoglyceride, a diglyceride, a triglyceride, or a combination thereof.

11. The formulation of any one of claims 1 to 10, wherein the oil comprises from about 50% to about 80% caprylic triglyceride (C8) and from about 20% to about 50% capric triglyceride (C10).

12. A formulation according to any preceding claim, wherein the formulation further comprises a flavouring agent.

13. The formulation of any preceding claim, wherein the formulation comprises a detectable amount of Compound 1, but no more than about 0.5% of Compound 1 relative to the peak area of ​​sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity or 40°C and 75% relative humidity for 1 month, 3 months, 6 months, 9 months or 12 months.

14. The formulation of any preceding claim, wherein the formulation comprises a detectable amount of Compound 2 but no more than about 0.5% of Compound 1 relative to the peak area of ​​sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity or 40°C and 75% relative humidity for 1 month, 3 months, 6 months, 9 months or 12 months.

15. The formulation of any preceding claim, wherein the formulation comprises detectable amounts of Compound 1 and Compound 2, but no more than about 1% of Compound 1 and Compound 2 relative to the peak area of ​​sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity or 40°C and 75% relative humidity for 1 month, 3 months, 6 months, 9 months or 12 months.

16. The formulation of any preceding claim, wherein the formulation comprises a detectable amount of Compound 3, but no more than about 0.2% of Compound 3 relative to the peak area of ​​sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity or 40°C and 75% relative humidity for 1 month, 3 months, 6 months, 9 months or 12 months.

17. The formulation of any preceding claim, wherein the formulation comprises a detectable amount of impurities, but no more than about 1.5% of total impurities, relative to the peak area of ​​sapropterin as measured by HPLC after storage at 25°C and 60% relative humidity or 40°C and 75% relative humidity for 1 month, 3 months, 6 months, 9 months or 12 months.

18. A formulation according to any preceding claim for use in a method of treating phenylketonuria and hyperphenylalaninemia.

19. A method for the treatment of phenylketonuria or hyperphenylalaninemia, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a formulation according to any preceding claim.

20. The method of treatment according to claim 19, wherein the treatment is for pediatric phenylketonuria or pediatric hyperphenylalaninemia.

Citation Information

Cited By

  • Sapropterin sustained release tablet and preparation method thereof

    CN122351183A

  • Sapropterin powder and preparation method thereof

    CN122624395A